

## HLS Appoints Ryan Lennox as General Counsel

TORONTO, May 7, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that Mr. Ryan C. Lennox has been named General Counsel. Reporting to the CEO, the General Counsel role will focus on supporting and enhancing the Company's acquisition efforts, corporate governance directives and general legal requirements.

"Ryan fills a strategic role within our organization, providing, among other things, a key resource in our efforts to identify, acquire and integrate other promising specialty assets," said Greg Gubitz, CEO of HLS. "During his six years at Amgen, he provided senior counsel on a diverse number of issues in multiple geographic markets, including cross-border negotiations, and built a deep understanding of the legal landscape in the Canadian healthcare industry. In addition, at a time when we have just recently completed our listing on the TSX Venture exchange, in his role as Corporate Secretary we will also benefit from his extensive expertise in corporate governance and compliance."

Since 2012, Mr. Lennox has been Director & Senior Counsel at Amgen Inc., responsible for all the legal affairs of Amgen's Canadian affiliate. In more recent years, he had taken on increasing responsibility at Amgen, including managing the legal team and affairs of Amgen's Intercontinental Region, comprised of Canada, Latin America, Turkey, Middle East and Africa. Mr. Lennox is called to the bar in both California and Ontario. Prior to joining Amgen, Mr. Lennox practiced corporate law at McDermott Will & Emery in San Diego, California and Stikeman Elliott in Toronto, Ontario, two international law firms where he advised a wide variety of clients on corporate finance, M&A, private equity, venture capital and other types of transactions.

### About HLS Therapeutics Inc.

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

### Forward-Looking Information

*This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the joint information circular of HLS and AMD dated February 5, 2018 in respect of the Arrangement, which has been filed on SEDAR and can be accessed at [www.sedar.com](http://www.sedar.com). Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.*

SOURCE HLS Therapeutics Inc.

For further information: HLS Contact Information: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [dave.mason@loderockadvisors.com](mailto:dave.mason@loderockadvisors.com); Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, [g.godin@hlstherapeutics.com](mailto:g.godin@hlstherapeutics.com)